The clinical-stage biopharmaceutical business Seelos Therapeutics Inc (Nasdaq: SEEL) was up 5.17% at $0.692 at the time of our last check in after-hours trading as it prepared to take part in a significant event.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
What event will SEEL be attending?
The 12th Annual LifeSci Partners Corporate Access Event will take place in San Francisco, California from January 9–11, 2023, and is being sponsored by Seelos Therapeutics (SEEL). Seelos Therapeutics is happy to learn that the annual event is taking place in person this year and will be taking part once more.
The acute suicidal behavior and attitudes in major depressive disorder, amyotrophic lateral sclerosis, and spinocerebellar ataxia, as well as recently provided preclinical data in Huntington’s and Parkinson’s diseases from its R&D event, are just a few of the topics that SEEL will be covering this year.
This month, SEEL released in vivo results showing that a single dosage of SLS-004 reduced the amount of alpha-synuclein (-synuclein) produced in the body. In an established -synuclein overexpressing animal model of Parkinson’s disease (PD), this decrease of -synuclein by SLS-004 led to a significant rise and recovery of neurodegeneration in tyrosine hydroxylase positive (TH+) dopaminergic neurons.
In the midbrain area known as the substantia nigra pars compacta (SNpc), TH+ dopaminergic neurons are known to deteriorate in PD patients. The four hallmark symptoms of Parkinson’s disease—tremors, stiffness, bradykinesia, and postural disturbances—are thought to be caused by this degeneration.
These findings imply that SLS-004 may provide significant promise as a gene treatment for Parkinson’s disease. These results from an in vivo PD model confirm and broaden earlier conclusions from in vitro research utilizing SLS-004. SLS-004 showed a therapeutically beneficial decrease in SNCA mRNA (-synuclein messenger RNA), which resulted in a decrease in the production of -synuclein protein.
How did SEEL continue to work on this?
In July 2021, Seelos Therapeutics (SEEL) released favorable in vivo findings from a trial using SLS-004 in a Vivo mouse model using CRISPR-dCas9 gene therapy technology, exhibiting down-regulation of SNCA mRNA and protein expression. The therapeutically desired 27% and 40% reductions in SNCA mRNA and protein expression were achieved with a single dosage of SLS-004. In August 2022, SEEL was chosen to receive funding from The Michael J. Fox Foundation for Parkinson’s Research to further preclinical research and development for the SLS-004 program. Seelos aims to expand the investigation of SLS-004 in PD.
